Researchers develop new way to evaluate tuberculosis treatments 18 May, 2021
Gregory Robertson, an assistant professor in the Department of Microbiology, Immunology and Pathology at CSU, is one of the first authors on the study. He said that the effectiveness of tuberculosis treatments has been judged by studying tissue cultures from infected patients. Photo: John Eisele/CSU Photography
Tuberculosis, a disease caused by the bacterium
Mycobacterium tuberculosis, is a serious global health threat. The disease caused an estimated 1.5 million deaths in 2019 and current methods often fail to predict treatment outcomes in patients.
Nature Communications provides an important new basis for comparing the effectiveness of different tuberculosis treatments and accelerating the development of shorter treatment regimens. The research team was led by scientists at the University of Colorado Anschutz Medical Campus with Colorado State University’s Mycobacteria Research Laboratories
COVID-19 is ravaging Brazil, and, in a disturbing new wrinkle that experts are working to understand, it appears to be killing babies and small children at an unusually high rate.
Share this article
Share this article
RARITAN, N.J., May 16, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO
® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO
® plus aspirin reduced first events by 15 percent among patients with PAD after LER. This analysis showed a very high burden of subsequent events and a consistent 14 percent reduction in both primary endpoint events and total vascular events over a median of 2.5 years. These data were presented as a late-breaking presentation during the virtual American College of Cardiology s 70